| Cell line name |
AR |
|---|
| Accession |
CVCL_E6X9 |
|---|
| Resource Identification Initiative |
To cite this cell line use: AR (RRID:CVCL_E6X9) |
|---|
| Comments |
Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
|---|
| HLA typing |
Source: PubMed=12836015
| Class I | | HLA-A | A*03,03 | | HLA-B | B*07,51 | | Class II | | HLA-DQ | DQB1*06:02,06:03 | | HLA-DR | DRB1*13:01,15:01:01 |
|
|---|
| Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
Age unspecified |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=9384677
Guckel B., Lindauer M., Rudy W., Habicht A., Siebels M., Kaul S., Bastert G., Meuer S.C., Moebius U.
CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.
Cytokines Mol. Ther. 1:211-221(1995) PubMed=12836015; DOI=10.1007/s00432-003-0445-7
Kayser S., Watermann I., Rentzsch C., Weinschenk T., Wallwiener D., Guckel B.
Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
J. Cancer Res. Clin. Oncol. 129:397-409(2003) PubMed=15365776; DOI=10.1007/s00262-004-0583-z; PMCID=PMC11034349
Guckel B., Stumm S., Rentzsch C., Marme A., Mannhardt G., Wallwiener D.
A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Cancer Immunol. Immunother. 54:129-140(2005) |
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2025 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 1 |
|---|
